CD8A and neoplasm: As shown in Figure 4B, tumor-bearing mice treated with DMXAA 3 days after the first vaccination (d+3) generated significantly higher E7-specific CD8+ T cell immune responses compared to tumor-bearing mice treated with DMXAA before vaccination (d-3) (p < 0.05).